
Nyxoah wins default ruling in patent case
Key points
- Nyxoah obtained a favourable default decision from the Unified Patent Court in Munich, Germany, in its patent infringement case against Inspire Medical Systems.
- The dispute concerns European Patent 2 760 534, covering technology relevant to Nyxoah's obstructive sleep apnea treatment business.
- Nyxoah is considering enforcement options, although it has not disclosed any damages award, injunction or specific enforcement timeline.
Nyxoah SA (NASDAQ:NYXH) obtained a favourable default decision from the Unified Patent Court in Munich, Germany, in its patent infringement case against Inspire Medical Systems concerning European Patent 2 760 534.
The decision concerns a patent dispute involving technology used in the treatment of obstructive sleep apnea, a condition that causes repeated interruptions in breathing during sleep.
Nyxoah filed its infringement action against Inspire and its European subsidiary in December 2025, alleging that the Inspire IV system infringed two European patents and seeking damages and injunctive relief.
The latest decision was issued by default in Nyxoah's favour, but the company has not disclosed the monetary value of any award, specific remedies granted or the timetable for implementing the decision.
Nyxoah develops neuromodulation treatments for obstructive sleep apnea, with its lead product, the Genio system, using leadless, battery-free hypoglossal nerve stimulation technology.
The Genio system received European CE marking in 2019 and US FDA approval in August 2025, while the patent dispute forms part of broader legal proceedings between Nyxoah and Inspire across European and US courts.
